NCT02102490 · OUTCOME

Number of Participants With Categorical Change From Baseline in Brief Pain Inventory Short Form (mBPI-sf) - Worst Pain Score

A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread · Source last updated 2020-01-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: Cycle 6 Day 1

What was measured

A self-reported scale that measures the severity of pain based on the average pain experienced over the past 24 hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine).

Analysis population: All randomized participants with a baseline and at least 1 post-baseline mBPI-sf data.

Groups in this outcome

Abemaciclib

200 mg abemaciclib given orally once every 12 hours for 28 days (1 cycle). Participants may continue to receive treatment until discontinuation criteria are met.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Abemaciclib	59

Reported measurements

Source class 1

Better

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Abemaciclib	18	Not reported	Not reported	Not reported	Not reported

No Change

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Abemaciclib	21	Not reported	Not reported	Not reported	Not reported

Worse

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Abemaciclib	20	Not reported	Not reported	Not reported	Not reported

Complete source fields

calculate Pct

false

classes

categories
measurements
group Id
OG000
value
18
title
Better
measurements
group Id
OG000
value
21
title
No Change
measurements
group Id
OG000
value
20
title
Worse

denoms

counts
group Id
OG000
value
59
units
Participants

description

groups

description
200 mg abemaciclib given orally once every 12 hours for 28 days (1 cycle). Participants may continue to receive treatment until discontinuation criteria are met.
id
OG000
title
Abemaciclib

param Type

COUNT_OF_PARTICIPANTS

population Description

All randomized participants with a baseline and at least 1 post-baseline mBPI-sf data.

reporting Status

POSTED

time Frame

Cycle 6 Day 1

title

Number of Participants With Categorical Change From Baseline in Brief Pain Inventory Short Form (mBPI-sf) - Worst Pain Score

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice